Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCC NASDAQ:LPTX NASDAQ:MBRX NASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.79-3.2%$2.69$1.29▼$7.12$9.40M2.19114,432 shs38,970 shsLPTXLeap Therapeutics$0.28-1.2%$0.31$0.22▼$4.79$11.70M-0.211.75 million shs1.96 million shsMBRXMoleculin Biotech$0.41+4.6%$0.57$0.25▼$3.65$12.33M1.54.57 million shs6.03 million shsQLGNQualigen Therapeutics$1.73$2.44$1.61▼$10.45$2.94M-0.15345,551 shs19,909 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis-6.09%-20.26%-32.48%-29.39%-19.91%LPTXLeap Therapeutics+1.02%-0.87%-9.41%-31.55%-89.83%MBRXMoleculin Biotech+3.73%-0.87%-42.33%-41.24%-83.79%QLGNQualigen Therapeutics+2.37%-3.35%-4.95%-54.11%-78.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.79-3.2%$2.69$1.29▼$7.12$9.40M2.19114,432 shs38,970 shsLPTXLeap Therapeutics$0.28-1.2%$0.31$0.22▼$4.79$11.70M-0.211.75 million shs1.96 million shsMBRXMoleculin Biotech$0.41+4.6%$0.57$0.25▼$3.65$12.33M1.54.57 million shs6.03 million shsQLGNQualigen Therapeutics$1.73$2.44$1.61▼$10.45$2.94M-0.15345,551 shs19,909 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis-6.09%-20.26%-32.48%-29.39%-19.91%LPTXLeap Therapeutics+1.02%-0.87%-9.41%-31.55%-89.83%MBRXMoleculin Biotech+3.73%-0.87%-42.33%-41.24%-83.79%QLGNQualigen Therapeutics+2.37%-3.35%-4.95%-54.11%-78.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCCIM Cannabis 0.00N/AN/AN/ALPTXLeap Therapeutics 2.00Hold$3.381,095.11% UpsideMBRXMoleculin Biotech 3.00Buy$4.00882.80% UpsideQLGNQualigen Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QLGN, LPTX, IMCC, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$4.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCCIM Cannabis$39.44M0.24N/AN/A$1.03 per share1.74LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/AQLGNQualigen Therapeutics$4.98M0.59N/AN/A($4.12) per share-0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCCIM Cannabis-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%11/14/2025 (Estimated)QLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/12/2025 (Estimated)Latest QLGN, LPTX, IMCC, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A8/12/2025Q2 2025IMCCIM Cannabis-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 million8/12/2025Q2 2025MBRXMoleculin Biotech-$0.39-$0.49-$0.10-$0.49N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCCIM CannabisN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCCIM Cannabis0.320.720.62LPTXLeap TherapeuticsN/A1.341.34MBRXMoleculin BiotechN/A1.151.15QLGNQualigen TherapeuticsN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCCIM Cannabis7.68%LPTXLeap Therapeutics30.46%MBRXMoleculin Biotech15.52%QLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipIMCCIM CannabisN/ALPTXLeap Therapeutics7.50%MBRXMoleculin Biotech2.10%QLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCCIM Cannabis3405.25 millionN/ANot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableMBRXMoleculin Biotech2030.29 million29.65 millionNot OptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableQLGN, LPTX, IMCC, and MBRX HeadlinesRecent News About These CompaniesFinancial Analysis: TherapeuticsMD (NASDAQ:TXMD) versus Qualigen Therapeutics (NASDAQ:QLGN)September 4, 2025 | americanbankingnews.comQualigen Therapeutics Amends Promissory Note with MarizymeAugust 27, 2025 | tipranks.comQualigen Therapeutics, Inc.: Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 30, 2025 | finanznachrichten.deQualigen Therapeutics Announces $4.5M Private PlacementJuly 29, 2025 | msn.comQualigen Therapeutics provides update on Nasdaq listing statusJuly 28, 2025 | msn.comQualigen Therapeutics Secures Nasdaq Compliance ExtensionJuly 28, 2025 | msn.comQualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 28, 2025 | finance.yahoo.comQualigen Therapeutics, Inc. Secures $4.5 Million Through Series A-3 Preferred Stock Private PlacementJuly 28, 2025 | quiverquant.comQQualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred StockJuly 28, 2025 | globenewswire.comQualigen Granted New Patents Covering 25 CountriesJuly 16, 2025 | manilatimes.netMQualigen Therapeutics shares surge after patent approvals in 25 countriesJuly 16, 2025 | msn.comQualigen Therapeutics, Inc. (QLGN) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQualigen Therapeutics faces potential Nasdaq delistingMay 21, 2025 | uk.investing.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics Faces Nasdaq Delisting NotificationMay 19, 2025 | tipranks.comQualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing DeficiencyMay 19, 2025 | quiverquant.comQQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QMay 19, 2025 | globenewswire.comMarizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo FinanceMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQLGN, LPTX, IMCC, and MBRX Company DescriptionsIM Cannabis NASDAQ:IMCC$1.79 -0.06 (-3.24%) Closing price 04:00 PM EasternExtended Trading$1.86 +0.08 (+4.19%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Leap Therapeutics NASDAQ:LPTX$0.28 0.00 (-1.22%) Closing price 04:00 PM EasternExtended Trading$0.28 0.00 (-0.14%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Moleculin Biotech NASDAQ:MBRX$0.41 +0.02 (+4.63%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (-0.49%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Qualigen Therapeutics NASDAQ:QLGN$1.73 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.71 -0.02 (-1.10%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
